Last reviewed · How we verify

NCT05159479

Defining Robust Predictors of Chemotherapy Related Cardiotoxicity

Status unknown Last updated 21 September 2023
What this trial tests

trial in Cardiotoxicity in 600 participants. Status unknown.

Timeline
13 October 2021
Primary endpoint
1 April 2024
1 July 2024

Quick facts

Lead sponsorUniversity College, London
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment600
Start date13 October 2021
Primary completion1 April 2024
Estimated completion1 July 2024
Sites1 location across United Kingdom

Conditions studied

Sponsor

University College, London

Who can join

18 and older, any sex, with Cardiotoxicity or Gastrointestinal Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observational prospective cohort study designed for patients with gastrointestinal cancers receiving a fluoropyrimidine based chemotherapy regimen.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Predicting cardiovascular events with fluoropyrimidine chemotherapy using a standard cardiovascular risk calculator.
    Abiodun A, Shawe-Taylor M, Tyebally S, Bagkeris E, et al · · 2024 · cited 3× · PMID 38845140 · DOI 10.1002/ehf2.14879

Verify or expand the search:

Other recruiting trials for Cardiotoxicity

Currently open trials in the same condition.

Other University College, London trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05159479.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing